This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Piper, K. E.
Right arrow Articles by Patel, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Piper, K. E.
Right arrow Articles by Patel, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 1999, p. 708-710, Vol. 43, No. 3
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Ketolide Treatment of Haemophilus influenzae Experimental Pneumonia

Kerryl E. Piper, Mark S. Rouse, James M. Steckelberg, Walter R. Wilson, and Robin Patel*

Division of Infectious Diseases and Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota

Received 23 April 1998/Returned for modification 22 July 1998/Accepted 4 December 1998

The MICs of HMR 3004 and HMR 3647 at which 90% of beta-lactamase-producing Haemophilus influenzae isolates were inhibited were 4 and 2 µg/ml, respectively. Both HMR 3004 and HMR 3647 were active against beta-lactamase-producing H. influenzae in a murine model of experimental pneumonia. As assessed by pulmonary clearance of H. influenzae, HMR 3004 was more effective (P < 0.05) than was azithromycin, ciprofloxacin, clarithromycin, erythromycin A, pristinamycin, or HMR 3647 in this model.

* Corresponding author. Mailing address: Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55902. Phone: (507) 255-7762. Fax: (507) 255-7767. E-mail: patel.robin{at}mayo.edu.

Antimicrobial Agents and Chemotherapy, March 1999, p. 708-710, Vol. 43, No. 3
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Tormakangas, L., Alakarppa, H., David, D. B., Leinonen, M., Saikku, P. (2004). Telithromycin Treatment of Chronic Chlamydia pneumoniae Infection in C57BL/6J mice. Antimicrob. Agents Chemother. 48: 3655-3661 [Abstract] [Full Text]  
  • Ackermann, G., Rodloff, A. C. (2003). Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide. J Antimicrob Chemother 51: 497-511 [Abstract] [Full Text]  
  • Kadota, J.-I., Ishimatsu, Y., Iwashita, T., Matsubara, Y., Tomono, K., Tateno, M., Ishihara, R., Muller-Serieys, C., Kohno, S. (2002). Intrapulmonary Pharmacokinetics of Telithromycin, a New Ketolide, in Healthy Japanese Volunteers. Antimicrob. Agents Chemother. 46: 917-921 [Abstract] [Full Text]  
  • Miyazaki, S., Fujikawa, T., Matsumoto, T., Tateda, K., Yamaguchi, K. (2001). Efficacy of azithromycin, clarithromycin and {beta}-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice. J Antimicrob Chemother 48: 425-430 [Abstract] [Full Text]  
  • Mitten, M. J., Meulbroek, J., Nukkala, M., Paige, L., Jarvis, K., Oleksijew, A., Tovcimak, A., Hernandez, L., Alder, J. D., Ewing, P., Or, Y. S., Ma, Z., Nilius, A. M., Mollison, K., Flamm, R. K. (2001). Efficacies of ABT-773, a New Ketolide, against Experimental Bacterial Infections. Antimicrob. Agents Chemother. 45: 2585-2593 [Abstract] [Full Text]  
  • Bonnefoy, A., Guitton, M., Delachaume, C., Le Priol, P., Girard, A.-M. (2001). In Vivo Efficacy of the New Ketolide Telithromycin (HMR 3647) in Murine Infection Models. Antimicrob. Agents Chemother. 45: 1688-1692 [Abstract] [Full Text]  
  • Odenholt, I., Löwdin, E., Cars, O. (2001). Pharmacodynamics of Telithromycin In Vitro against Respiratory Tract Pathogens. Antimicrob. Agents Chemother. 45: 23-29 [Abstract] [Full Text]  
  • Duong, M., Simard, M., Bergeron, Y., Bergeron, M. G. (2001). Kinetic Study of the Inflammatory Response in Streptococcus pneumoniae Experimental Pneumonia Treated with the Ketolide HMR 3004. Antimicrob. Agents Chemother. 45: 252-262 [Abstract] [Full Text]  
  • Singh, K. V., Zscheck, K. K., Murray, B. E. (2000). Efficacy of Telithromycin (HMR 3647) against Enterococci in a Mouse Peritonitis Model. Antimicrob. Agents Chemother. 44: 3434-3437 [Abstract] [Full Text]  
  • Yamaguchi, T., Hirakata, Y., Izumikawa, K., Miyazaki, Y., Maesaki, S., Tomono, K., Yamada, Y., Kamihira, S., Kohno, S. (2000). In Vitro Activity of Telithromycin (HMR3647), a New Ketolide, against Clinical Isolates of Mycoplasma pneumoniae in Japan. Antimicrob. Agents Chemother. 44: 1381-1382 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»